A multi-country study to assess the effect of a treatment with moxidectin pour-on during the dry period on milk production in dairy cows.

A randomized clinical study was conducted in a total of 45 commercial dairy farms in France (14 farms), Germany (28 farms) and the UK (3 farms) to evaluate the effect of an anthelmintic treatment on milk yield in the subsequent lactation. A total of 1287 animals with suspected exposure to Ostertagia ostertagi were included in the study. Animals were treated during the dry period (7-77days before parturition) with moxidectin pour-on (Cydectin® 0.5% Pour-On, Zoetis; 638 animals) or left untreated (649 animals) according to a randomized block design. Animals were either heifers (n=296) or multiparous cows (n=991). The milk production was monitored at regular intervals after treatment up to 335days after lactation, and analysed using a general linear mixed model with the milk production as outcome variable and several random effects. The effect on milk yield after anthelmintic treatment over the whole subsequent lactation varied from no effect (-0.43kg/day; P=0.35) to an increase of milk yield with 2.35kg/day (P=0.01), depending on the study region and parity of the cows. Lactation curve analysis suggested that the treatment effect was mainly caused by a slower decay of the milk production in the treated animals compared to untreated animals. The present study highlights the beneficial effect of a topical treatment with moxidectin before parturition on milk yield in the subsequent lactation, as well as the importance of a careful evaluation of nematode exposure risk based on local grazing management practices to guide and target production-based anthelmintic treatment decisions.

Anthelmintic resistance to ivermectin and moxidectin in gastrointestinal nematodes of cattle in Europe.

Anthelmintic resistance has been increasingly reported in cattle worldwide over the last decade, although reports from Europe are more limited. The objective of the present study was to evaluate the efficacy of injectable formulations of ivermectin and moxidectin at 0.2 mg per kg bodyweight against naturally acquired gastro-intestinal nematodes in cattle. A total of 753 animals on 40 farms were enrolled in Germany (12 farms), the UK (10 farms), Italy (10 farms), and France (8 farms). Animals were selected based on pre-treatment faecal egg counts and were allocated to one of the two treatment groups. Each treatment group consisted of between 7 and 10 animals. A post-treatment faecal egg count was performed 14 days (±2 days) after treatment. The observed percentage reduction was calculated for each treatment group based on the arithmetic mean faecal egg count before and after treatment. The resistance status was evaluated based on the reduction in arithmetic mean faecal egg count and both the lower and upper 95% confidence limits. A decreased efficacy was observed in half or more of the farms in Germany, France and the UK. For moxidectin, resistance was confirmed on 3 farms in France, and on 1 farm in Germany and the UK. For ivermectin, resistance was confirmed on 3 farms in the UK, and on 1 farm in Germany and France. The remaining farms with decreased efficacy were classified as having an inconclusive resistance status based on the available data. After treatment Cooperia spp. larvae were most frequently identified, though Ostertagia ostertagi was also found, in particular within the UK and Germany. The present study reports lower than expected efficacy for ivermectin and moxidectin (based on the reduction in egg excretion after treatment) on European cattle farms, with confirmed anthelmintic resistance on 12.5% of the farms.

Safety and efficacy of an aroA-deleted live vaccine against avian colibacillosis in a multicentre field trial in broilers in Morocco.

The safety and efficacy of an aroA-deleted live vaccine against avian colibacillosis (Poulvac(®) E. coli) was evaluated in broilers in a multicentre field trial. The trial sites consisted of 18 paired bird houses (randomly assigned to either the vaccination or the control treatment groups) located in 15 farms in three different regions of Morocco. A field dose of vaccine was administered on day of hatch by the spray route. Both clinical and performance parameters were compared between vaccinated and control groups, in which the experimental unit was defined as the individual bird house. No adverse reactions attributable to the vaccine were observed throughout the study. Non-inferiority of the vaccinated bird houses versus the control houses during a 2-week period post vaccination was statistically demonstrated for mortality and average daily weight gain. Vaccine efficacy was confirmed based on significant differences between vaccinated and unvaccinated groups measured for the full duration of the trial, including colibacillosis-like lesions observed at slaughter (1.7 versus 3.5%; P = 0.0054), total mortality (9.3 versus 10.3%; P = 0.0203), average daily weight gain (47.8 versus 46.2 g/day; P = 0.0006), average number of antibiotic treatment days (0.5 versus 2.0; P = 0.0008) and percentage of the birds that was marketed (90.0 versus 89.0%; P = 0.0309). In conclusion, the vaccine was demonstrated to be both safe and efficacious under field conditions.